Mean combination index (CI) values at 50% and 80% growth inhibition (IC50, IC80) derived from combined treatment experiments
Cell line . | Drug combination . | Dose ratio of imatinib to combined drug . | CI: IC50 . | CI: IC80 . |
|---|---|---|---|---|
| K562 | Imatinib + As2O3 | 1:2 | 1.16 ± 0.23± | 0.86 ± 0.08+ |
| Imatinib + decitabine | 1:1.24 | 0.52 ± 0.09+++ | 0.64 ± 0.05+++ | |
| Mo7p210 | Imatinib + As2O3 | 1:20 | 1.04 ± 0.08± | 0.84 ± 0.02++ |
| Imatinib + decitabine | 1:13.3 | 0.75 ± 0.1++ | 0.7 ± 0.15++ | |
| AR230-r | Imatinib + As2O3 | 1:0.25 | 1.10 ± 0.12± | 0.89 ± 0.24± |
| Imatinib + decitabine | 1:0.25 | 0.81 ± 0.07++ | 0.92 ± 0.15± | |
| Baf/BCR-ABL-s | Imatinib + As2O3 | 1:0.5 | 1.21 ± 0.1- | 0.93 ± 0.06± |
| Imatinib + decitabine | 1:2 | 1.09 ± 0.01± | 0.93 ± 0.03± | |
| Baf/BCR-ABL-r | Imatinib + As2O3 | 1:0.83 | 1.43 ± 0.16- - | 1.09 ± 0.14± |
| Imatinib + decitabine | 1:0.5 | 1.10 ± 0.07± | 0.93 ± 0.09± | |
| Ba/F3p210Y253F | Imatinib + As2O3 | 1:0.2 | 1.11 ± 0.18± | 0.82 ± 0.01++ |
| Imatinib + decitabine | 1:0.4 | 1.18 ± 0.19± | 0.49 ± 0.08+++ | |
| Ba/F3p210M35IT | Imatinib + As2O3 | 1:0.31 | 1.19 ± 0.16± | 1.00 ± 0.23± |
| Imatinib + decitabine | 1:1.25 | 0.9 ± 0.12± | 0.63 ± 0.04+++ |
Cell line . | Drug combination . | Dose ratio of imatinib to combined drug . | CI: IC50 . | CI: IC80 . |
|---|---|---|---|---|
| K562 | Imatinib + As2O3 | 1:2 | 1.16 ± 0.23± | 0.86 ± 0.08+ |
| Imatinib + decitabine | 1:1.24 | 0.52 ± 0.09+++ | 0.64 ± 0.05+++ | |
| Mo7p210 | Imatinib + As2O3 | 1:20 | 1.04 ± 0.08± | 0.84 ± 0.02++ |
| Imatinib + decitabine | 1:13.3 | 0.75 ± 0.1++ | 0.7 ± 0.15++ | |
| AR230-r | Imatinib + As2O3 | 1:0.25 | 1.10 ± 0.12± | 0.89 ± 0.24± |
| Imatinib + decitabine | 1:0.25 | 0.81 ± 0.07++ | 0.92 ± 0.15± | |
| Baf/BCR-ABL-s | Imatinib + As2O3 | 1:0.5 | 1.21 ± 0.1- | 0.93 ± 0.06± |
| Imatinib + decitabine | 1:2 | 1.09 ± 0.01± | 0.93 ± 0.03± | |
| Baf/BCR-ABL-r | Imatinib + As2O3 | 1:0.83 | 1.43 ± 0.16- - | 1.09 ± 0.14± |
| Imatinib + decitabine | 1:0.5 | 1.10 ± 0.07± | 0.93 ± 0.09± | |
| Ba/F3p210Y253F | Imatinib + As2O3 | 1:0.2 | 1.11 ± 0.18± | 0.82 ± 0.01++ |
| Imatinib + decitabine | 1:0.4 | 1.18 ± 0.19± | 0.49 ± 0.08+++ | |
| Ba/F3p210M35IT | Imatinib + As2O3 | 1:0.31 | 1.19 ± 0.16± | 1.00 ± 0.23± |
| Imatinib + decitabine | 1:1.25 | 0.9 ± 0.12± | 0.63 ± 0.04+++ |
Analysis of at least 3 independent experiments (each of which contained triplicate analysis) was performed at the given fixed molar dose ratio. Dose ratios were selected by combining approximately equipotent antiproliferative doses of the single agents. All agents were used at clinically achievable and relevant dose ranges.5,35,36 Gradual levels of synergy are marked as recommended by the manufacturer of the Calcusyn software32 : +++, synergism; ++, moderate synergism; +, slight synergism; ±, nearly additive; -, slight antagonism; and - -, moderate antagonism.